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hiodo@med.Abstract: Diseases of muscle may be congenital or acquired. They cause muscle w
without sensory loss. The onset, distribution, and clinical course help to differen
type of muscle disorder. The diagnostic workup may include laboratory exam
electrodiagnostic studies, and muscle biopsy. A definitive diagnosis leads to better
making with regard to treatment, genetic education, prognosis, functional expectat
the impact of exercise on muscle function.
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INTRODUCTION
Simply put, a myopathy is a muscle disorder. Historically, classification systems
classic clinical presentations and, later, relied on muscle biopsy findings. More
classification has been refined by genetic analysis and reverse genetics, which
identification of the defective gene byproduct and which has led to an understandi
pathophysiology of specific myopathies. Rapid evolution of the science of myopa
made classification a continually moving process, but one reasonable example is
Table 1.
MUSCULAR DYSTROPHIES
The dystrophinopathies are known historically as Duchenne and Becker muscula
phy. Caused by defects at the Xp21 locus, the disease is caused by the lack of or def
protein dystrophin. A defect to this critical cell membrane protein causes cell damag
muscle contraction because the relationship between actin and the membran
dystrophin-glycoprotein complex is lost. The result is cell necrosis and apoptosis. O
common genetic defects to components of the dystrophin-glycoprotein compl
defects that range from minimal deficit to fatal disease [1].
The classic presentation of Duchennemuscular dystrophy is disease recognition
the ages of 3 and 5, with delayed motor development and with cognitive and b
impairment. Initial presentation includes hip greater than shoulder girdle weakne
Gower maneuver present by the age of 5-8. Extensor weakness is greater tha
although neck flexor weakness is common. Calf pseudohypertrophy may be
Achilles tendon and iliotibial band contractures occur by age 6 years, with knee an
flexor andwrist extensor contractures occurring later. Boys typically require a whee
the age of 10 years with progressive contractures and scoliosis. Oral prednis
prolong motor skill ability. Cardiomyopathy is seen with left ventricular ejection
deficits and systolic hypertension. Tall right precordial R-waves and deep, narrow
in left leads is a common electrocardiographic finding. Respiratory failure is unive
only 25% of patients surviving or being ventilator free by the age of 21 years. H
overall life expectancy has significantly improved in recent decades due to the use o
ventilation.
Limb girdle muscular dystrophy (LGMD) is a heterogeneous set of disorders t
common presentation of axial and proximal limb weakness. Onset can range f
childhood through adulthood, depending on the disorder. Recessive forms h
identified that are related to defects that affect sarcoglycans, calpain 3, and dysfe
dysferlinopathies are also known as Miyoshi myopathy and LGMD type 2B, with d
the 2p13 locus of the human genome. Dysferlin is a protein that is responsible for T-tu
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S75PM&R Vol. 5, Iss. 5S, Supplement 1, 2013homeostasis and muscle membrane repair. Animal m
this disorder are currently being used to study aden
ated virus vector transfer therapy [2]. There also
somal dominant limb girdle dystrophies, two in p
that affect collagen VI and caveolin-3.
Facioscapulohumeral dystrophy, with an inciden
20,000, is characterized by profound scapular, fa
proximal limb weakness. Hearing loss is common b
functionally limiting. Cardiac and respiratory dysf
are rare. There are 2 types, one due to a deletion
whereas type 2 results in a methylation defect. M
dystrophy is now classified into 2 types, the first c
ized by a CTG repeat expansion 30 of DMPK, an
which is a CTG repeat expansion in CNBP. These ex
alter the processing of certainmessenger RNAs, whic
cell dysfunction. In the myotonic dystrophies, al
splicing at exon 29 affects Ca(V)1.1, a calcium
responsible for controlling excitation-contraction c
The degree of the skipping correlates with the d
muscle weakness [3]. The disorder has multiorgan
ment, including ocular, endocrine, cardiac, repr
gastrointestinal, and skin. Muscle weakness is mos
nent in the face, neck, and distal extremities. Ma
balding and mental retardation are characteristic.
Oculopharyngeal muscular dystrophy results fr
expansions in PABPN1, a nuclear protein involve
polyadenylation of messenger RNA. It presents wi
and dysphagia. Emery-Driefuss muscular dystrop
forms, autosomal dominant due to lamin A/C de
X-linked due to a defect in the protein emerin
involvement includes the cervical spine and dis
extremities. Cardiac involvement is common, and
death can occur. Congenital muscular dystrophy
caused by gene defects to a number of gene products
Table 1. Myopathies
Congenital Ac
Dystrophies Infla
Dystrophinopathies Para
LGMD Endo
FSH Toxic
Myotonic Ste
OPMD Sta
EDMD Sarc
Others
Congenital myopathies
Central core
Nemaline
Centronuclear
CFTD
Metabolic myopathies
Mitochondrial myopathies
CFTD  congenital fiber type disproportion; FSH  facioscap
dystrophy; LGMD  limb girdle muscular dystrophy; OPMD  oc
geal muscular dystrophy; EDMD  Emery-Driefuss muscular dying merosin, fukutin, FKRP, and a-7 integrin.of
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The FHL1 muscular dystrophies are associated
fects at Xq26.3 and can present with multiple phe
including scapuloperoneal dystrophy, bent spine sy
and reducing body myopathy. The case can be m
these myofibrillar myopathies, characterized by Z-li
tegration, are characteristic, given the common lowe
axial weakness and atrophy seen. However, the d
weakness is highly variable, and the onset has b
anywhere between the ages of 6 years and 75 y
Defects in collagen VI can result in a number of ne
cular disorders, including Ullrich congenital musc
trophy, Bethlem myopathy, and intermediate phe
depending on the severity of the gene defect [5].
CONGENITAL MYOPATHIES
Congenital myopathies have historically been cat
and named based on their biopsy appearance. A
theme in the congenital myopathies is disruption o
tion-contraction coupling in skeletal muscle [6]. N
myopathy is due to defects in contractile filaments; n
rods are Z-disk–derived material. Their accumula
give rise to many defects, including -actin (autosom
inant with variable penetrance), nebulin (autosom
sive), or other thin filament–associated proteins
tropomyosin 2 and 3, troponin T2, or cofilin. N
myopathies can have onset throughout life, with
severity, although a common pattern includes involv
proximal and facial muscles and respiratory insuf
without ophthalmoplegia.
The other congenital myopathies are due to disru
calcium homeostasis at the level of the T-tubule an
plasmic reticulum. In central core disease, there is an
of mitochondria, with central cores that run the leng
myofiber. The gene defect is RYR1, the ryanodine
responsible for calcium homeostasis on the sarcop
ticulum. The autosomal dominant form is a cen
disease, characterized by proximal weakness and l
involvement. The autosomal recessive form is mini
opathy. The SEPN-1 defect results in multiminico
the mutation found at 1p36-13. The gene product
protein N1, is responsible for calcium homeostasis
tects the cell against redox-related cellular dama
phenotype presents with slowly progressive proxim
ness, axial weakness and deformities, and progressi
ratory failure [7].
Centronuclear myopathy is an X-linked disorde
mutations in the MTM1 gene for myotubulin, wh
phosphoinositide phosphatase protein. There also
tosomal dominant form that results in a defect in th
gene. This causes a defect in the protein dynamin-2,
responsible for endocytosis and interactions betwe
and the microtubule network in the muscle.
The operational definition of congenital fiber typ
d
ory
s
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S76 Chiodo ACQUIRED MYOPATHY/DYSTROPHIESthan type 2 fibers by at least 35%-40%. For this dia
is necessary that no other histologic finding is seen o
because small type 1 fibers are common in other co
such as the congenital myopathies, spinal muscular
myotonic dystrophy, and Ullrich muscular dystrop
tiple gene defects have been implicated in CFTD.
autosomal dominant defects in TPM3 have been im
in this disorder, yet they all result in similar clinica
of mild to moderate weakness, with progressive re
decline. Defects in p.R168H, p.R168C, and RYR1
highly variable phenotypes [8].
METABOLIC MYOPATHIES
Defects in fat oxidation can lead to myopathy. The
carnitine palmitoyl transferase 2 deficiency, althou
disorders exist, including trifunctional protein d
and very-long-chain acetyl-CoA dehydrogenase de
Glycogen storage disorders also cause myopathy. T
well characterized is McArdle disease, due to myop
rylase deficiency at genetic site 11q13. Tarui disea
phosphofructokinase deficiency has also been ex
studied.
Abnormal serum lactate accumulation in aerobic
testing can be more helpful than baseline serum lact
in patients with mitochondrial myopathies. This te
cific but not highly sensitive. Myophosphorylase d
or McArdle disease (1/100,000 incidence) can be e
with the ischemic forearm test, in which a lack o
lactate with exercise is indicative of a glycolytic
defect. Normal or exaggerated rises in ammonia ser
centrations are seen.Myoadenylate deaminase defici
most common metabolic pathway defect in skeleta
(1 in 100) will result in normal or decreased lac
decreased ammonia concentration [9].
Pompe disease, or acidmaltase deficiency, is an a
recessive disorder caused by the deficiency of the l
enzyme acid -glucosidase and results in cellular l
and cytoplasmic glycogen accumulation. The severi
Table 2. Proposed classification of inflammatory my
Entity
Immune myopathy with perimysial
pathology
Perimy
cells;
Myovasculopathy Interm
dama
Immune polymyopathy Muscle
Immune myopathy with endomysial
pathology
Histiocytic inflammatory myopathy Histioc
Inflammatory myopathy with vacuoles,
aggregates and mitochondrial
pathology
As statease, depending on the extent of the mutation, can vary fr, it
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severe hypotonia and cardiac hypertrophy in the
months of life to adult-onset disease. Patients typic
proximal weakness as in the limb girdle dystrophies
incidence of respiratory weakness in higher in Pom
ease. There currently is available enzyme replacem
apy for this disorder, which does result in glycogen d
in cardiac and skeletal muscle. However, it does no
glycogen deposition in other cells, especially in neu
Therefore, adeno-associated virus-mediated gene th
being explored in animal models of this disease. A
tional downside of enzyme therapy is that it leads
GAA antibodies; tolerance strategies need to be d
around infusions [10].
Mitochondrial myopathies include chronic pro
external ophthalmoplegia, mitochondrial encepha
lactic acidosis and stroke-like episodes, and myocl
lepsy with ragged red fibers. Electrodiagnostic stu
commonly abnormal but not pathognomonic (see
Coenzyme Q supplementation is recommended for
with this disorder [11].
ACQUIRED INFLAMMATORY MYOPATH
Inflammatory muscle disorders include dermato
polymyositis, inclusion body myositis (IBM), skeleta
vasculitis in rheumatologic disorders (systemic
rheumatoid arthritis, systemic lupus erythemato
Sjogren syndrome), and sarcoid myopathy [12-14]
matory myopathies have an incidence of 2-8 per
adults with the adult peak between 45 and 55 year
women predominate 3 to 2. A pathologic classific
immune and inflammatory myopathies has been p
as associated with typical muscle biopsy, clinical, a
ratory features [15], which is summarized in Table
IBM has an incidence of 2-5 per million adults wi
at 50-70 years old and male predominance. IBM is
ered the most prevalent idiopathic inflammatory m
in the geriatric population, although cancer-related
omyositis is more common. Patients with cance
ies
Pathology Clinical
ammation, perivascular B
necrosis, regeneration
Polymyositis, dermatomyositis
anti-Jo-1 and others; also ela
and capillary vessel Dermatomyositis, childhood a
adult
sis Paraneoplastic; anti-SRP and
CoAR
Brachiocervical inflammatory
myopathy
redominate Sarcoid, immunizations
Inclusion body myositisopath
sial infl
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S77PM&R Vol. 5, Iss. 5S, Supplement 1, 2013a muscle biopsy study of older persons with cancer
associated with dermatomyositis in this population
lung, ovarian, pancreatic, stomach, colorectal, a
Hodgkin lymphoma. Ongoing cancer screening sho
tinue for 5 years after the diagnosis of dermatomyos
elderly because several years may elapse between the
muscle disease and detection of the precipitating ca
Genetic associations with polymyositis and derm
sitis in HLA class I and II genes have been iden
genetic relationship to IBM is less established, altho
studies have shown that there may be susceptibility
but further characterization is required [16]. Autoa
unique to the inflammatory myopathies are seen
than 50% of patients. Anti-Jo 1 is found in polymyo
dermatomyositis, whereas anti Mi-2 is seen in derm
sitis. Rituximab has been found to decrease disease a
depleting B cells. Antimitochondrial antibodies h
been identified in slightly more than 11% of patie
One-third of these patients had primary biliary
one-third had cardiac involvement (arrhythmias
creased ejection fraction), and one-third had decreas
ratory function, occasionally to the point of requiri
lation.
An important mimic for myopathy in the elderly
tion is polymyalgia rheumatica (PMR). Rapid onset
der pain and stiffness is a hallmark of PMR, althou
and pelvic muscle pain is common. Systemic sign
low-grade fever, anorexia, fatigue, and weight los
seen in up to 40% of patients. Sedimentation rate is
in inflammatory myopathies but a high sedimenta
higher than 40 mm/h, is the sole abnormality in P
Distinguishing among these disorders is important f
ing treatment. Polymyositis and dermatomyositis ar
with prednisone and IVIG. Steroid-sparing strategie
cyclosporine and tacrolimus. Hydroxychloroquine
for the skin manifestations of dermatomyositis. No
treatment strategy has been identified for IBM.
TOXIC MYOPATHIES
The sheer number of people who take statins (more
million Americans) would seem tomagnify the impo
this disorder. However, significant statin-induced m
affects fewer than 5%, with rhabdomyolysis in fe
0.1% [18]. Patho-anatomy and physiology of statin
thies start with their metabolism by the cytochrome
3A4 system; with competition by concomitant dru
there is an resultant increased risk of myopathy. C
comedications are clarithromycin, mibefradil, verap
fazodone, cyclosporine, diltiazem, and itraconazol
statin and pravastatin use a different metabolic
which alleviates this drug-drug interaction conc
lipophilic cerivastatin, lovastatin, and simvastatin
myotoxic. Gemfibrozil is a lower-risk additive agent for chers
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lesterol control than fenofibrate. Vitamin D deficie
have an additive effect such that vitamin replacemen
in relative muscle protection and improvement. The
nism of the myopathy is not clear.
However, it is now clear that genetic variants an
tions in the SLCO1B1, cytochrome P- P450, and
genes may determine individual susceptibility to st
opathy. Statins may also initiate immune-mediated
necrotizing and inflammatory myopathy that are un
during statin therapy. The unmasking or aggravatin
ious metabolic myopathies and other neuromuscul
ders has been characterized in persons who are usin
including hypokalemic and mitochondrial myopath
same is true of McArdle disease and postsynaptic ne
cular junction disorders. Drug-induced lysosomal
quine and amiodarone), antimicrotubular (colchi
vinca alkaloids), and myofibrillar (emetine, ipecac)
thies have also been reported during statin use [19]
High-dose statin treatment can result in as m
10-fold increase in the risk for myopathy. Medicatio
tion is the only known antidote to this myopathy. H
once patients have recovered muscle function, t
sometimes be effectively treated with every-other-da
with minimal adverse effects and relatively effect
density lipoprotein cholesterol management [20]
biopsy is useful in distinguishing among inflammat
cle disease, dystrophies, vasculitis, and mitochondr
ders. Statin-related myopathies show nonspecific
consistent with mitochondrial respiratory chain dys
(ragged red fibers, increased lipid, cytochrome-oxid
ative fibers). However, granuloma formation has a
seen in patients with statin myopathy and eleva
levels.
Steroid myopathy is due to the muscle proteolysis
steroids. Steroids also slow down the rate of protein s
in muscle and facilitate amino acid mobilization fro
cle. The steroid effect on muscle is dose dependent,
ing significantly at a dose of 30 mg of prednison
Exercise mitigates these effects, and every-other-da
may help as well.
SARCOPENIA
Sarcopenia is seen in 20% of all persons over the a
years and may be due to malnutrition, hormone de
inactivity, or chronic disease (chronic obstructive pu
disease, renal disease, liver disease, rheumatoid
cancer, congestive heart failure, Crohn disease). Ev
of sarcopenia should include thyroid function, vi
level, growth hormone, and, in men, serum test
[21]. Vitamin D therapy is controversial from the sta
of how effective it is in improving sarcopenia. Test
replacement in men shows a definite improvement io- mass and strength. Growth hormone replacement increases
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S78 Chiodo ACQUIRED MYOPATHY/DYSTROPHIESmuscle mass but not strength. This finding and the
effects seen in older persons leave questions rega
relative benefit-to-risk ratio.
ELECTROMYOGRAPHY IN MYOPATHY
Electromyography (EMG) is helpful in identifying
ence of a myopathy by evaluating motor units a
recruitment as well as identifying likely muscle nec
inflammation as inferred by the presence of abnorm
taneous activity. Electrodiagnosis is also important
out other disorders thatmaymimic amyopathy by e
the pattern of involvement and by directing the c
location for a muscle biopsy. It may also be used to
response to treatment.
Nerve conduction studies (NCS) are typically n
myopathies; however, low compound muscle actio
tial amplitudes may be present if the myopathy
and/or affects distal musculature because distal mu
most typically used in NCS. Sensory responses are
to be normal, except in disorders that cause both a m
and neuropathy, for example, critical illness neurom
or amyloid. Typically, at least 1 motor and 1 sensor
performed in the arm and in the leg, and the study ex
depending on those findings. EMG and/or NCS al
differentiation between muscle disease and defects
muscular transmission (both pre- and postsynapt
ders). If diffusely low compoundmuscle action pote
present, then Lambert-Eaton Myasthenic syndrom
be considered.
EMG examination should include proximal a
muscles, and should include clinically weak musc
longed insertional activity and abnormal spontaneo
ity may be identified, depending on the type of m
Myotonic potentials may be seen with channelopa
specific toxic myopathies (see Table 3). Complex r
discharges, although more common in chronic ne
disorders, may also be encountered in myopathies
neous activity is greatest in proximal muscles in poly
Table 3. Spontaneous activity in myopathies
Myopathies With
Fibrillation Potentials
Myopathies
Myotoni
Polymyositis/dermatomyositis Myotonic dystrop
Inclusion body myositis Myotonia conge
Sarcoid myopathy Paramyotonia co
Progressive muscular
dystrophies
Hyperkalemic pe
paralysis
Centronuclear myopathy Centronuclear m
Acid maltase deficiency Acid maltase de
Carnitine deficiency Colchicine myop
Colchicine myopathy Chloroquine myo
Chloroquine myopathy
Critical illness myopathy
Infectious myopathiesrse
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and/or dermatomyositis, with the thoracic paraspi
cles targeted because they are unlikely to be abnorm
degenerative spine disease. Classic changes include
plitude, short duration, polyphasic motor unit poten
early recruitment pattern may be seen because a gre
ber of motor units are needed to generate a low force
the presence of a chronic myopathy, such as inclus
myositis, a mixture of both long- and short-duratio
units may be present. EMG is typically normal in P
sarcopenia.
EMG is effective in evaluating patients with s
congenital myopathy. In a study of 62 young patient
EMG evidence of myopathy, 2 had evidence of ne
disorder, and 5 were normal. Routine muscle biop
mens in these patients showed 50 with myopathy an
nonspecific findings. A final diagnosis in these pati
DMD (n  27), Becker muscular dystrophy (1), co
muscular dystrophy (9), dermatomyositis (4), lim
muscular dystrophy (6), unidentified muscle dis
neurogenic disorder (4), and nonspecific findings
sensitivity of EMG was more than 95% in iden
myopathy in this group of patients; sensitivity im
minimally but significantly by adding turns and am
analysis [24].
EMG has been studied in a population of patie
mitochondrial myopathies. NCS were abnormal in 3
cases, with the finding of an associated sensorimoto
multifocal neuropathy affecting the lower more
upper extremities. Needle examination was abno
54.5% of patients, with myopathic motor unit chan
in proximal lower more than the upper limb musc
proportion of patients with abnormalities did n
among the different mitochondrial myopathies [25]
SKELETAL DEFORMITY IN MYOPATHY
A common cause for physiatric evaluation of these p
the presence of skeletal deformity. An excellent r
provided by Finsterer and Strobl [26]. Spine deform
a common feature in the muscular dystrophies an
inherited myopathies. Scoliosis is seen in 90% of
with dystrophinopathy. However, it is also commonl
FSH, collagen VI myopathies, laminopathies, CFTD (
central core, and multicore myopathies. Bent spine sy
or camptocormia, is commonly associated with glute
ness and increases with standing. It is commonly seen
linopathies, nemalinemyopathy, andmyotonic dystrop
1 and 2. A differential diagnosis includes dermato
polymyositis, CIDP, inclusion body myositis, moto
disease, and postsynaptic neuromuscular junction d
Dropped head syndrome is most common with facio
humeral dystrophy but can be seen in laminopathies,
myopathies, myotonic dystrophies type 1 and 2, mitoc
ital
hy
ymyopathy, and acid maltase deficiency. Differential diagnosis
tsynap
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S79PM&R Vol. 5, Iss. 5S, Supplement 1, 2013considerations include motor neuron disease and pos
neuromuscular junctiondisorders.Hyperlordosis can
dystrophinopathies, LGMD, FSH dystrophy, and l
thies. Hyperkyphosis is seen in dystrophinopathies an
plasties. Rigid spine is seen in laminopathies, EDMD
multicore, and multiminicore myopathies.
Other skeletal anomalies include scapular, pe
chest wall changes. Scapula winging is universally
facioscapulohumeral dystrophy. However, it also ca
in many of the limb girdle dystrophies, EDMD, la
thies, and acid maltase deficiency. Pectus excavatum
carinatum, and anteroposterior flattening of the che
seen in any of the congenital myopathies as we
dystrophinopathies. Pelvic obliquities are found
laminopathies, and congenital MP with type 1 p
nance.
Joint contractures are also commonly seen in
myopathies. In the dystrophinopathies, contractur
iliotibial band, hip flexors, knees, and ankles are
EDMD, knee, elbow, Achilles, and cervical spine
tures are seen. Laminopathies and Ullrich myopathy
proximal contractures, whereas Bethlem myopathy
distal contractures. Limb girdle MD 2a (calpain)
(dysferlinopathy) are associated with ankle cont
Central cord patients frequently have contractures
tients with myotonic dystrophy commonly have hi
tion and knee flexion contractures.
Myopathies can also be associated with joint hyp
ity, hyperlaxity, subluxation, or dislocation. Comm
ciations in dystrophinopathies include hip sublux
mitochondrial myopathies and hip dislocations i
core myopathy. Generalized joint laxity is seen in t
gen VI myopathies, LGMD 2E (-sarcoglycan), m
core disease, CMP, merosin-, and CMD.
Toe walking is seen in dystrophinopathies, lamin
EDMD, and dysferlinopathies. Not surprisingly, equ
contractures can be seen in these disorders, partic
dystrophinopathies and laminopathies. Club foot is
central core and multicore disease. Arthrogryposis
any foot deformity as can collagen VI myopathies, c
clear myopathy, CFTD, and Emery-Dreifuss musc
trophy.
EXERCISE IN MYOPATHY
Overall, the limited body of literature on exercise in
thies is favorable in this regard. In McArdle disease
training improved cardiac output, work capacity, an
tive capacity as measured by increased mitochon
zyme concentrations [27]. In inflammatorymyopath
resistive exercise improves aerobic capacity, endura
fatigue. There is evidence that messenger RNA exp
influenced by exercise, with a decrease in proinfla
and profibrotic expression, which influences the coursetic
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the disease [28]. Of 12 studies completed on ex
inflammatory myopathies, none saw an increase in
activity or pain. Strength was not influenced by the
regimen. In patients with chronic inflammatory myo
resistive training, aerobic exercise, and home exer
prove strength and function [29]. Resistance trainin
per week in sarcopenia is effective in improving
muscle mass, and associated mobility deficits. Add
tine to the exercise regimen provides further benefi
protein diet or supplements are not effective without
and provide no additive advantage [21].
Creatine has a role in anaerobic muscle energy
and is important in mitochondrial respiration funct
postulated that supplementation would have an
muscle performance in patients with myopathy.
been shown to be the case in the muscular dystrophi
mitochondrial encephalopathy, lactic acidosis, and
like episodes, whereas the effect in myotonic dystro
McArdle disease was not demonstrated [30]. The ad
creatine does increase muscle mass and function in
with chronic inflammatory myopathy who are unde
resistance and aerobic exercise program [29].
CLINICAL PEARLS
● Manymyopathies can now be classified by genetic
which allows for identification of the defective
product. So-called congenital myopathies have his
been categorized and named based on their biopsy
ance.
● In DMD, oral prednisone may prolong motor ski
Overall life expectancy has significantly improved
decades due to the use of assisted ventilation.
● Along with muscle weakness, most prominentl
face, neck, and distal extremities, individuals w
tonic myopathy may have characteristic male fron
ing.
● Mitochondrial myopathies, such as chronic pro
external ophthalmoplegia; mitochondrial encepha
lactic acidosis, and stroke-like episodes, and m
epilepsy with ragged red fibers, may benefit fro
zyme Q supplementation.
● IBM is considered the most prevalent idiopathic in
tory myopathy in the geriatric population, altho
cer-related dermatomyositis is more common. In
the elderly, ongoing cancer screening should con
5 years after the diagnosis of dermatomyositis. To
effective treatment has been identified for IBM.
● Polymyositis and dermatomyositis are treated w
nisone and IVIG. Steroid-sparing strategies includ
sporine and tacrolimus. Hydroxychloroquine is
the skin manifestations of dermatomyositis.
● The steroid effect on muscle is dose dependent, in
of significantly at a dose of 30 mg of prednisone daily. The
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S80 Chiodo ACQUIRED MYOPATHY/DYSTROPHIESeffect of steroid myopathy may be lessened with
and with reducing steroid dosing (such as every o
dosing) when tolerable.
● In addition to exercise, creatine supplementation
lated to improve muscle performance in patie
myopathy due to its role in anaerobic muscle ener
ery and mitochondrial respiration.
● In patients with suspected inflammatory myopat
pling the thoracic paraspinal muscles may be
detecting spontaneous activity in a region unlik
affected by confounding degenerative spine disea
imal and distal limb musculature should be samp
needle EMG to characterize myopathy.
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